Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05904106
Title	Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT)
Acronym	VINCENT
Recruitment	Not yet recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Technische Universitat Dresden
Indications	acute myeloid leukemia with mutated NPM1
Therapies	Cytarabine Azacitidine + Venetoclax Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Cytarabine + Mitoxantrone
Age Groups:	adult \| senior
Covered Countries	DEU